Neurocrine Biosciences Announces the Appointment Of
W. Thomas Mitchell to Its Board of Directors
W. Thomas Mitchell to Its Board of Directors
SAN DIEGO, Nov. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has elected W. Thomas Mitchell to its Board of Directors effective immediately. Mr. Mitchell is the current Chairman and former Chief Executive Officer of Genencor International (Nasdaq: GCOR).
"We are fortunate to have a person of Tom Mitchell's caliber join our Board of Directors. Tom brings to the board, experience not only in the industry, but more critically in the day to day operations of a successful operating company," said Gary Lyons, President and Chief Executive Officer of Neurocrine Biosciences. "His expertise and knowledge will be a valuable resource for Neurocrine's diversified pipeline and future growth."
Mr. Mitchell was named Chief Executive Officer of Genencor International in 1991. Since then, the company's annual revenues have grown from under $30 million to over $325 million. He successfully managed the acquisition and integration of three major businesses to build the global enterprise that is now Genencor. An industry leader, Mr. Mitchell has participated in a number of important policy initiatives including the 1999 federal executive order that created the national bioenergy initiative. Mr. Mitchell has also served as a member of the Governor's Council on Biotechnology in California, which was responsible for helping to improve the state's competitiveness in the mid-1990's. He has also previously served on the Advisory Boards of the Chemical Engineering School at Cornell University, Ithaca, New York and the University of Iowa's School of Engineering.
He received his Bachelor of Science degree in Chemical Engineering from Drexel University, Philadelphia, Pennsylvania. He also completed the Executive Development Program at the University of Michigan.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com .
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X62122248
SOURCE Neurocrine Biosciences, Inc.